Table 2.
PSA outcomes during followup
| TRT vs Reference
|
||||||||
|---|---|---|---|---|---|---|---|---|
| All Pts | High Risk Pts | Nonhigh risk Pts | p Value | p Value* | ||||
| Treatment group: | ||||||||
| No. pts | 103 | 26 | 77 | |||||
| Median ng/ml/yr PSAV (IQR), No. | 0.002 | (0.001–0.003), 89 | 0.002 | (0.001–0.011), 22 | 0.001 | (0.001–0.002), 67 | 1.000 | |
| No. suspected BCR (%)† | 4 | (4) | 4 | (15) | 0 | (0) | 0.015 | 0.03 |
| No. BCR defined as a single PSA greater than 0.2 ng/ml (%) | 2 | (2) | 2 | (8) | 0 | (0) | ||
| No. discontinued TRT for reason other than suspected BCR (%)‡ | 15 | (15) | 2 | (8) | 13 | (17) | ||
| Reference group: | ||||||||
| No. pts | 50 | 15 | 35 | |||||
| Median ng/ml/yr PSAV (95% CI), No. | 0.0002 | (−0.001–0.010), 27 | 0.018 | (−0.012–0.106), 10 | −0.0003 | (−0.001–0.004), 17 | ||
| No. suspected BCR (%)† | 8 | (16) | 8 | (53) | 0 | (0) | ||
| No. BCR defined as a single PSA greater than 0.2 ng/ml (%) | 5 | (10) | 5 | (33) | 0 | (0) | ||
PSA velocity only calculated for patients with 3 or more PSA levels in 1 or more years.
*
Suspected recurrence with exclusion of patients with T3a/3b disease.
†
Suspected BCR recorded when charted in medical record, if patient was referred to radiation oncologist for increasing PSA and/or if patient underwent salvage therapy for increasing PSA.
‡
Included concern for increasing PSA, cardiovascular side effects, increased risk of relapse, cost, no symptomatic improvement, underwent operation or procedure unrelated to CaP, supraphysiological T level, transient ischemic attack or leg pain.